KRAS Inhibitors Market Size and Forecast: A New Era in Oncology KRAS Inhibitors: Transforming Oncology Treatment Landscape KRAS mutations are among the most common oncogenic drivers in cancers such as lung, colorectal, and pancreatic cancers. For decades, KRAS was considered “undruggable,” but recent breakthroughs have led to the development of targeted therapies that are reshaping...